Catalyst Pharmaceuticals (CPRX) Return on Capital Employed (2011 - 2026)
Catalyst Pharmaceuticals posted quarterly Return on Capital Employed of 26.94% for Q1 2026, down 316.0% year-on-year from 12.47% in Q1 2025, and down 2.73% on a QoQ basis from 27.7% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 16 years of Return on Capital Employed data on file, last reported at 26.94% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 316.0% year-over-year to 26.94%; the trailing twelve-month figure through Mar 2026 stood at 26.94% (down 316.0% YoY), and the FY2025 full-year result was 31.04%, down 509.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 26.94%, down from 27.7% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 37.05% in Q2 2023 and bottomed at 14.7% in Q2 2024.
- The 5-year median for Return on Capital Employed is 28.24% (2024), against an average of 27.81%.
- The widest annual swing landed in 2024, when Return on Capital Employed slumped 2235 bps; it then jumped 1472 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 34.31% in 2022, then sank by 31 bps to 23.75% in 2023, then climbed by 19 bps to 28.24% in 2024, then slipped by 2 bps to 27.7% in 2025, then fell by 3 bps to 26.94% in 2026.
- The last three Return on Capital Employed figures came in at 26.94% (Q1 2026), 27.7% (Q4 2025), and 29.31% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 26.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.94% |
| Dec 31, 2025 | 27.70% |
| Sep 30, 2025 | 29.31% |
| Jun 30, 2025 | 29.42% |
| Mar 31, 2025 | 30.11% |
| Dec 31, 2024 | 28.24% |
| Sep 30, 2024 | 27.45% |
| Jun 30, 2024 | 14.70% |
| Mar 31, 2024 | 16.36% |
| Dec 31, 2023 | 23.75% |
| Sep 30, 2023 | 20.48% |
| Jun 30, 2023 | 37.05% |
| Mar 31, 2023 | 35.88% |
| Dec 31, 2022 | 34.31% |
| Sep 30, 2022 | 32.79% |
| Jun 30, 2022 | 30.97% |
| Mar 31, 2022 | 27.32% |
| Dec 31, 2021 | 25.75% |
| Sep 30, 2021 | 24.68% |
| Jun 30, 2021 | 24.57% |
| Mar 31, 2021 | 22.40% |
| Dec 31, 2020 | 25.68% |
| Sep 30, 2020 | 30.16% |
| Jun 30, 2020 | 41.01% |
| Mar 31, 2020 | 44.63% |
| Dec 31, 2019 | 39.56% |
| Sep 30, 2019 | 12.91% |
| Jun 30, 2019 | -23.52% |
| Mar 31, 2019 | -58.66% |
| Dec 31, 2018 | -64.68% |
| Sep 30, 2018 | -38.45% |
| Jun 30, 2018 | -30.00% |
| Mar 31, 2018 | -25.06% |
| Dec 31, 2017 | -33.51% |
| Sep 30, 2017 | -53.68% |
| Jun 30, 2017 | -48.83% |
| Mar 31, 2017 | -46.89% |
| Dec 31, 2016 | -46.55% |
| Sep 30, 2016 | -46.88% |
| Jun 30, 2016 | -45.43% |
| Mar 31, 2016 | -41.21% |
| Dec 31, 2015 | -34.64% |
| Sep 30, 2015 | -28.39% |
| Jun 30, 2015 | -24.82% |
| Mar 31, 2015 | -28.40% |
| Dec 31, 2014 | -37.39% |
| Sep 30, 2014 | -33.33% |
| Jun 30, 2014 | -39.26% |
| Mar 31, 2014 | -56.71% |
| Dec 31, 2013 | -41.42% |
| Sep 30, 2013 | -51.74% |
| Mar 31, 2012 | -125.06% |
| Dec 31, 2011 | -136.99% |
| Sep 30, 2011 | -105.49% |